{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:57:50Z","timestamp":1789192670308,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>China is a country burdened with a high incidence of both tuberculosis (TB) and HIV, Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an important early complication in TB and HIV co-infected patients, but data from China are limited. Additionally, as an integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen becomes the first-line treatment, concerns have arisen regarding the potential increase in the incidence of paradoxical TB-IRIS. Nevertheless, the existing data are inconclusive and contradictory.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective study at Chongqing Public Health Clinical Center from January 2018 to December 2021. We collected demographic and clinical data of HIV\/TB co-infected patients who initiated ART. We described the patient characteristics, identified predictors for TB-IRIS, and determined clinical outcomes. The Statistical Package for Social Science (SPSS 25) was used to analyse the data. Continuous variables were compared using Student\u2019s t-test or rank sum test. Counting data were compared using the chi-square test or Fisher\u2019s exact test. The variables with statistical significance in the univariate analysis were added to the binary logistic regression. A p-value less than 0.05 was considered statistically significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 384 patients co-infected with naive HIV and pulmonary TB (PTB) who were given ATT and ART combination were included. 72 patients (18.8%) developed paradoxical TB-IRIS with a median of 15 (12, 21) days after initiating ART. Baseline age\u2009\u2264\u200940years, CD4\u2009+\u2009T-cell counts\u2009\u2264\u200950cells\/\u00b5L, HIV viral load\u2009\u2265\u2009500,000 copies\/mL were found to be significantly associated with development of paradoxical TB-IRIS. Mortality rates were similar in the TB-IRIS (n\u2009=\u20095, 6.9%) group and non-TB-IRIS (n\u2009=\u200913, 4.2%) group. Interestingly, CD4<jats:sup>+<\/jats:sup> T-cell counts recovery post-ART was significant higher in the TB-IRIS group when compared to the non-TB-IRIS group at the end of 24 weeks (P\u2009=\u20090.004), as well as at 48 weeks (P\u2009=\u20090.015). In addition, we consider that INSTI- based ART regimen do not increased the risk of Paradoxical TB-IRIS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Paradoxical TB-IRIS, while often leading to clinical deterioration and hospitalization, is generally manageable. It appears to have a positive impact on the recovery of CD4\u2009+\u2009T-cell counts over time. Importantly, our data suggest that INSTI-based ART regimens do not elevate the risk of TB-IRIS. Thus, paradoxical TB-IRIS should not be considered an impediment to initiating ART in adults with advanced immunodeficiency, except in the case of tuberculous meningitis (TBM).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08897-3","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T12:03:40Z","timestamp":1704197020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in initiating ART among HIV-Infected patients in China-risk factors and management"],"prefix":"10.1186","volume":"24","author":[{"given":"Honghong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"issue":"1","key":"8897_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.imbio.2013.07.004","volume":"219","author":"HT Tran","year":"2014","unstructured":"Tran HT, Van den Bergh R, Vu TN, TB-IRIS Study Group, et al. The role of monocytes in the development of tuberculosis-associated Immune reconstitution inflammatory syndrome. Immunobiology. 2014;219(1):37\u201344.","journal-title":"Immunobiology"},{"key":"8897_CR2","doi-asserted-by":"publisher","first-page":"101863","DOI":"10.1016\/j.tube.2019.101863","volume":"118","author":"PM Cevaal","year":"2019","unstructured":"Cevaal PM, Bekker LG, Hermans S. TB-IRIS pathogenesis and new strategies for intervention: insights from related inflammatory disorders. Tuberculosis (Edinb). 2019;118:101863.","journal-title":"Tuberculosis (Edinb)"},{"issue":"2","key":"8897_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/pathogens12020210","volume":"12","author":"R Vignesh","year":"2023","unstructured":"Vignesh R, Balakrishnan P, Tan HY, et al. Tuberculosis-Associated Immune reconstitution inflammatory Syndrome-An extempore game of misfiring with Defense arsenals. Pathogens. 2023;12(2):210.","journal-title":"Pathogens"},{"issue":"16","key":"8897_CR4","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","volume":"365","author":"FX Blanc","year":"2011","unstructured":"Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with Tuberculosis. N Engl J Med. 2011;365(16):1471\u201381.","journal-title":"N Engl J Med"},{"issue":"6","key":"8897_CR5","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2217\/fmb.15.9","volume":"10","author":"PE Namale","year":"2015","unstructured":"Namale PE, Abdullahi LH, Fine S, et al. Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Future Microbiol. 2015;10(6):1077\u201399.","journal-title":"Future Microbiol"},{"issue":"16","key":"8897_CR6","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","volume":"365","author":"DV Havlir","year":"2011","unstructured":"Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 Infection and Tuberculosis. N Engl J Med. 2011;365(16):1482\u201391.","journal-title":"N Engl J Med"},{"issue":"6","key":"8897_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/COH.0000000000000502","volume":"13","author":"NF Walker","year":"2018","unstructured":"Walker NF, Stek C, Wasserman S, et al. The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research. Curr Opin HIV AIDS. 2018;13(6):512\u201321.","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"8897_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/QAI.0b013e3182255dc2","volume":"58","author":"W Worodria","year":"2011","unstructured":"Worodria W, Massinga-Loembe M, Mazakpwe D, et al. Incidence and predictors of mortality and the effect of Tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB\/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr. 2011;58(1):32\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"8897_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jinf.2006.01.002","volume":"53","author":"W Manosuthi","year":"2006","unstructured":"Manosuthi W, Kiertiburanakul S, Phoorisri T, et al. Immune reconstitution inflammatory syndrome of Tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect. 2006;53(6):357\u201363.","journal-title":"J Infect"},{"key":"8897_CR10","doi-asserted-by":"crossref","unstructured":"Karmakar S, Sharma SK, Vashishtha R et al. Clinical characteristics of tuberculosis-associated immune reconstitution inflammatory syndrome in north Indian population of HIV\/AIDS patients receiving HAART. Clin Dev Immunol. 2011;239021.","DOI":"10.1155\/2011\/239021"},{"issue":"1","key":"8897_CR11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1186\/s12879-020-05225-x","volume":"20","author":"M Xue","year":"2020","unstructured":"Xue M, Xie R, Pang Y, et al. Prevalence and risk factors of paradoxical Tuberculosis associated immune reconstitution inflammatory syndrome among HIV-infected patients in Beijing, China. BMC Infect Dis. 2020;20(1):554.","journal-title":"BMC Infect Dis"},{"key":"8897_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12879-020-4786-5","volume":"20","author":"NBR de Sa","year":"2020","unstructured":"de Sa NBR, Ribeiro-Alves M, da Silva TP, et al. Clinical and genetic markers associated with Tuberculosis, HIV-1 Infection, and TB\/HIV-immune reconstitution inflammatory syndrome outcomes. BMC Infect Dis. 2020;20:59.","journal-title":"BMC Infect Dis"},{"key":"8897_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijid.2019.04.015","volume":"84","author":"CAM Silva","year":"2019","unstructured":"Silva CAM, Graham B, Webb K, et al. A pilot metabolomics study of Tuberculosis immune reconstitution inflammatory syndrome. Int J Infect Dis. 2019;84:30\u20138.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"8897_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/archinte.162.1.97","volume":"162","author":"E Navas","year":"2002","unstructured":"Navas E, Mart\u00edn-D\u00e1vila P, Moreno L, et al. Paradoxical reactions of Tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med. 2002;162(1):97\u20139.","journal-title":"Arch Intern Med"},{"issue":"6","key":"8897_CR15","first-page":"1053","volume":"38","author":"S Tansuphasawadikul","year":"2007","unstructured":"Tansuphasawadikul S, Saito W, Kim J, Tansuphasawadikul S, Saito W, Kim J, et al. Outcomes in HIV-infected patients on antiretroviral therapy with Tuberculosis. Southeast Asian J Trop Med Public Health. 2007;38(6):1053\u201360.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"8897_CR16","doi-asserted-by":"publisher","first-page":"e63541","DOI":"10.1371\/journal.pone.0063541","volume":"8","author":"G Narendran","year":"2013","unstructured":"Narendran G, Andrade BB, Porter BO, et al. Paradoxical Tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary Tuberculosis in India and the potential role of IL-6 in prediction. PLoS ONE. 2013;8:e63541.","journal-title":"PLoS ONE"},{"issue":"1","key":"8897_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13690-023-01044-z","volume":"81","author":"ZY Chen","year":"2023","unstructured":"Chen ZY, Deng XY, Zou Y, et al. A spatio-temporal bayesian model to estimate risk and influencing factors related to Tuberculosis in Chongqing, China, 2014\u20132020. Arch Public Health. 2023;81(1):42.","journal-title":"Arch Public Health"},{"issue":"1","key":"8897_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1186\/s12879-020-05304-z","volume":"20","author":"L Zhang","year":"2020","unstructured":"Zhang L, Xing W, Zhou J, et al. Characteristics of Tuberculosis patients in the integrated Tuberculosis control model in Chongqing, China: a retrospective study. BMC Infect Dis. 2020;20(1):576.","journal-title":"BMC Infect Dis"},{"key":"8897_CR19","doi-asserted-by":"publisher","first-page":"586390","DOI":"10.3389\/fmed.2020.586390","volume":"7","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Yang Z, Liu M, et al. Independent risk factors for deaths due to AIDS in Chongqing, China: does Age Matter? Front Med (Lausanne). 2021;7:586390.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"8897_CR20","doi-asserted-by":"publisher","first-page":"e006669","DOI":"10.1136\/bmjopen-2014-006669","volume":"5","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Xiao Q, Zhou L, et al. The AIDS epidemic and economic input impact factors in Chongqing, China, from 2006 to 2012: a spatial-temporal analysis. BMJ Open. 2015;5(3):e006669.","journal-title":"BMJ Open"},{"issue":"11","key":"8897_CR21","first-page":"1182","volume":"27","author":"AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association","year":"2021","unstructured":"AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association. Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV\/AIDS. Chin J AIDS STD. 2021;27(11):1182\u2013201.","journal-title":"Chin J AIDS STD"},{"key":"8897_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1473-3099(08)70184-1","volume":"8","author":"G Meintjes","year":"2008","unstructured":"Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516\u201323.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"8897_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.7326\/0003-4819-157-5-201209040-00004","volume":"157","author":"K Naidoo","year":"2012","unstructured":"Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with Tuberculosis: findings from the SAPiT trial. Ann Intern Med. 2012;157(5):313\u201324.","journal-title":"Ann Intern Med"},{"issue":"6","key":"8897_CR24","first-page":"670","volume":"14","author":"L Li","year":"2021","unstructured":"Li L, Li J, Chai C, et al. Association of CD4 T cell count and optimal timing of antiretroviral therapy initiation with immune reconstitution inflammatory syndrome and all-cause mortality for HIV-infected adults with newly diagnosed pulmonary Tuberculosis: a systematic review and meta-analysis. Int J Clin Exp Pathol. 2021;14(6):670\u20139.","journal-title":"Int J Clin Exp Pathol"},{"issue":"5","key":"8897_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3851\/IMP2108","volume":"17","author":"W Worodria","year":"2012","unstructured":"Worodria W, Menten J, Massinga-Loembe M, et al. Clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome in patients with tuberculosis-HIV coinfection. Antivir Ther. 2012;17(5):841\u20138.","journal-title":"Antivir Ther"},{"issue":"12","key":"8897_CR26","first-page":"1282","volume":"11","author":"W Burman","year":"2007","unstructured":"Burman W, Weis S, Vernon A, et al. Frequency, severity and duration of immune reconstitution events in HIV-related Tuberculosis. Int J Tuberc Lung Dis. 2007;11(12):1282\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"key":"8897_CR27","first-page":"804","volume":"131","author":"SK Sharma","year":"2010","unstructured":"Sharma SK, Dhooria S, Barwad P, et al. A study of TB-associated immune reconstitution inflammatory syndrome using the consensus case-definition. Indian J Med Res. 2010;131:804\u20138.","journal-title":"Indian J Med Res"},{"issue":"1","key":"8897_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/QAI.0b013e318288b39d","volume":"63","author":"M Schomaker","year":"2013","unstructured":"Schomaker M, Egger M, Maskew M, et al. Immune recovery after starting ART in HIV-infected patients presenting and not presenting with Tuberculosis in South Africa. J Acquir Immune Defic Syndr. 2013;63(1):142\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"8897_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijid.2015.04.008","volume":"35","author":"AE Ezeamama","year":"2015","unstructured":"Ezeamama AE, Mupere E, Oloya J, et al. Age, sex, and nutritional status modify the CD4\u2009+\u2009T-cell recovery rate in HIV-tuberculosis co-infected patients on combination antiretroviral therapy. Int J Infect Dis. 2015;35:73\u20139.","journal-title":"Int J Infect Dis"},{"issue":"16","key":"8897_CR30","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1097\/01.aids.0000432456.14099.c7","volume":"27","author":"D Laureillard","year":"2013","unstructured":"Laureillard D, Marcy O, Madec Y, et al. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. AIDS. 2013;27(16):2577\u201386.","journal-title":"AIDS"},{"issue":"1","key":"8897_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/1545109712457711","volume":"12","author":"N Kumarasamy","year":"2013","unstructured":"Kumarasamy N, Venkatesh KK, Vignesh R, et al. Clinical outcomes among HIV\/tuberculosis-coinfected patients developing immune reconstitution inflammatory syndrome after HAART initiation in South India. J Int Assoc Provid AIDS Care. 2013;12(1):28\u201331.","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"11","key":"8897_CR32","first-page":"262","volume":"10","author":"CM Quinn","year":"2020","unstructured":"Quinn CM, Poplin V, Kasibante J, et al. Tuberculosis IRIS: Pathogenesis, Presentation, and management across the Spectrum of Disease. Life (Basel). 2020;10(11):262.","journal-title":"Life (Basel)"},{"issue":"7","key":"8897_CR33","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/S2352-3018(19)30154-7","volume":"6","author":"G Meintjes","year":"2019","unstructured":"Meintjes G, Brust JCM, Nuttall J, et al. Management of active Tuberculosis in adults with HIV. Lancet HIV. 2019;6(7):e463\u201374.","journal-title":"Lancet HIV"},{"key":"8897_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12981-016-0118-7","volume":"13","author":"N Gopalan","year":"2016","unstructured":"Gopalan N, Chandrasekaran P, Swaminathan S, et al. Current trends and intricacies in the management of HIV-associated pulmonary Tuberculosis. AIDS Res Ther. 2016;13:34.","journal-title":"AIDS Res Ther"},{"issue":"1","key":"8897_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.medmal.2020.09.005","volume":"51","author":"A Gaillet","year":"2021","unstructured":"Gaillet A, Calin R, Flandre P, et al. Increased risk of IRIS-associated Tuberculosis in HIV-infected patients receiving integrase inhibitors. Infect Dis Now. 2021;51(1):90\u20133.","journal-title":"Infect Dis Now"},{"key":"8897_CR36","first-page":"405","volume":"15","author":"M Psichogiou","year":"2017","unstructured":"Psichogiou M, Basoulis D, Tsikala-Vafea M, Vlachos S, Kapelios CJ, Daikos GL. Integrase strand transfer inhibitors and the emergence of immune reconstitution inflammatory syndrome (IRIS). Curr HIV Res. 2017;15:405\u201310.","journal-title":"Curr HIV Res"},{"issue":"8","key":"8897_CR37","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/hiv.13117","volume":"22","author":"J Kim","year":"2021","unstructured":"Kim J, Nam HJ, Kang SJ, et al. Integrase strand transfer inhibitor treatment does not increase the incidence of immune reconstitution inflammatory syndrome in HIV-infected koreans. HIV Med. 2021;22(8):705\u201314.","journal-title":"HIV Med"},{"issue":"12","key":"8897_CR38","doi-asserted-by":"publisher","first-page":"e1002706","DOI":"10.1371\/journal.pmed.1002706","volume":"15","author":"C Kityo","year":"2018","unstructured":"Kityo C, Szubert AJ, Siika A, et al. REALITY trial team. Raltegravir-intensified initial antiretroviral therapy in advanced HIV Disease in Africa: a randomised controlled trial. PLoS Med. 2018;15(12):e1002706.","journal-title":"PLoS Med"}],"updated-by":[{"DOI":"10.1186\/s12879-024-09080-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000}}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08897-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08897-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08897-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T10:02:46Z","timestamp":1709287366000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08897-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8897"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08897-3","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12879-024-09080-y","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"18 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12879-024-09080-y","URL":"https:\/\/doi.org\/10.1186\/s12879-024-09080-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Chongqing Public Health Medical Center (approval No. 2023-054-01-KY). Written informed consent for the study by the patients was waived by the Ethics Committee of Chongqing Public Health Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}